Article
Macrophage migration inhibitory factor promotes resistance to MEK blockade in KRAS mutant colorectal cancer cells.
Molecular oncology - 1 Aug 2018
Cheon Seul-Ki, Kim Hwang-Phill, Park Ye-Lim, Jang Jee-Eun, Lim Yoojoo, Song Sang-Hyun, Han Sae-Won, Kim Tae-You
Abstract excerpt
Although MEK blockade has been highlighted as a promising antitumor drug, it has poor clinical efficacy in KRAS mutant colorectal cancer (CRC). Several feedback systems have been described in which inhibition of one intracellular pathway leads to activation of a parallel signaling pathway, thereby decreasing the effectiveness of single-MEK targeted therapies. Here, we investigated a bypass mechanism of resistance...
Topics
- Apoptosis
- Cell Line, Tumor
- Colorectal Neoplasms
- Diphenylamine
- Drug Resistance, Neoplasm
- Humans
- Intramolecular Oxidoreductases
- MAP Kinase Signaling System
- Macrophage Migration-Inhibitory Factors
- Mitogen-Activated Protein Kinases
- Mutation
- Protein Kinase Inhibitors